AMR — antimicrobial resistance — is the indication driving most non-GLP-1 peptide pipeline activity outside oncology. Antimicrobial peptides offer mechanisms small-molecule antibiotics cannot match: membrane disruption, biofilm penetration, and resistance evolution that runs slower because the mechanism doesn't depend on a single binding pocket.
WHO guideline updates, ESCMID and ESCMID Global readouts, and academic clinical work land here. Programs covered include Peptilogics on prosthetic-joint biofilm, Fedora Pharmaceuticals' FPI-2119 lactivicin against carbapenem-resistant gram-negatives, work on Acinetobacter baumannii and MRSA, and Longhorn Vaccines' DRG5-BD11 peptidoglycan platform.
Stories here cover candidate readouts, the policy fight on stewardship and reimbursement, and the WHO and CDC publications that frame the urgency. See #antimicrobial-peptide for the chemistry and #antibiotic-resistance for the alternate tag.
A Frontiers in Bioinformatics review published March 17, 2026 from Tope Abraham Ibisanmi and colleagues at UNSW Sydney documents how computational antimicrobial peptide discovery has collapsed from decades to weeks. The review covers big-data mining, molecular dynamics simulations, and AI methods that capture complex sequence-activity relationships and predict novel AMPs from genomic and metagenomic data. The headline example: one large language model approach produced 18 de novo peptides of which 17 were active (94.4% hit rate) over a 48-day discovery cycle. The framing complements the broader AMP-as-AMR-response thesis with Aifeity, the University of Bonn, and Cesar de la Fuente at Penn — and lands as Cesar de la Fuente's Penn lab launches new generative AMR molecules into ESKAPE-pathogen testing.
A Frontiers in Medicine review published in 2026 consolidates the case for antimicrobial peptides (AMPs) as anticancer therapeutics and vaccine adjuvants. The cationic, amphipathic architecture that makes AMPs effective against bacterial membranes also enables selective electrostatic interactions with negatively charged malignant cell membranes — driving rapid membrane disruption and cell lysis. Beyond direct membrane effects, the review documents AMP-induced inhibition of DNA replication and protein synthesis, mitochondrial dysfunction, and tumor angiogenesis suppression. The piece also catalogs AMPs with adjuvant properties that boost vaccine immune responses against cancer and infectious disease. The work joins the Houston Methodist CAMPER MRSA paper, the Nature Communications few-shot Acinetobacter pipeline, and the Manchester penicillin-biosynthesis paper as part of the AMP wave through April–May 2026.
A Nature Communications paper describes a deep-learning pipeline that uses pre-trained protein language models combined with few-shot fine-tuning to identify antimicrobial peptides effective against Acinetobacter baumannii, a WHO critical-priority pathogen. The classification, ranking, and regression modules collaboratively prioritize candidates with high predicted activity, expanding the chemical space accessible to data-poor AMR targets. Lead candidates showed potent in vitro activity against carbapenem-resistant clinical isolates.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
Findings from the Oxford-led BARNARDS II study presented at ESCMID Global 2026 showed WHO-recommended ampicillin plus gentamicin first-line therapy is likely effective for only 1 in 4 neonatal sepsis infections in low- and middle-income countries. Data were collected across 13 tertiary neonatal units in Pakistan, Bangladesh, and Nigeria from February 2024 to October 2025, intensifying the case for AMR-driven peptide alternatives.
Fedora Pharmaceuticals presented eight posters at ESCMID Global 2026 in Munich today highlighting FPI-2119, a first-in-kind derivative of the lactivicin class for Gram-negative infections. As a non-β-lactam antibiotic, FPI-2119 is not susceptible to β-lactamases. Posters demonstrated concentration-dependent bactericidal activity and low resistance frequency against Pseudomonas aeruginosa, maintained activity against β-lactamase-expressing E. coli strains, and activity against resistant Campylobacter, Salmonella, and Shigella.
A new Nature Biomedical Engineering paper introduces HMD-AMP, a protein language model-based approach that outperforms prior methods at identifying evolutionarily distant antimicrobial peptides. Applied to host and gut microbiome genomes of nine mammals, HMD-AMP revealed over 37 million predicted AMPs. Of 91 experimentally validated high-confidence sequences, 74 showed strong antibacterial activity and 48 were evolutionarily remote from known AMPs, including four with broad-spectrum activity at low toxicity.
The European Society of Clinical Microbiology & Infectious Diseases (ESCMID) Global 2026 opened today at Messe München, running April 17-21 with ~18,000 international participants. Antimicrobial resistance dominates the agenda, with presentations featuring novel antimicrobial peptides, peptide-antibody hybrids, and AI-driven AMP discovery platforms. ESCMID is the largest international clinical microbiology and infectious diseases conference worldwide.
Longhorn Vaccines and Diagnostics presents preclinical data on DRG5-BD11, a bispecific IgM monoclonal antibody targeting bacterial peptidoglycan and HSP16.3 across gram-positive, gram-negative, and mycobacterial pathogens. In vitro assays demonstrated 82% opsonophagocytic killing against E. coli and 74% against Mycobacterium smegmatis, supporting its potential as a broad-spectrum anti-infective for AMR-driven sepsis.